Clinical Observation On Serum And Urine TSGF Levels In Intracranial Tumors

BACKGROUND: Malignant tumor is the main disease threatening people's health and life. The morbidity of malignant tumor is increasing every year and now become the second cause of death following heart disease. The early diagnosis and treatment for tumor is still difficult. In generally, the early treatment for tumor can obtain the better result than that of latter one. Therefore, the early finding, early diagnosis and early treatment appear to be very important in dealing with tumor. Tumor marker is a studing focus recently as it plays a very important role for early diagnosis of malignant tumor. But, it has not been found a good tumor mark belong to intracranial malignant tumors. Tumor specific growth factor (TSGF) is a new malignant tumor marker and has high sensitivity, specificity and wide spectrum, and it has not a clear relationship with intracranial malignant tumors.OBJECTIVE: The main purpose of this article are: 1,To investigate the levels of tumor specific growth factor (TSGF) in serum and urine of human intracranial tumors during pre-operation and post-operation ; 2,To evaluate the value of TSGF for early diagnosis, predicting prognosis and other clinical significance for intracranial malignant tumors; 3,To inquire into whether the levels of TSGF is associated with diameter of intracranial malignant tumors. 4,To judge whether it has the same effect measuring TSGF in serum and urine, and whether TSGF is a good tumor marker for intracranial malignant tumors.METHODS: TSGF levels were detected by biochemical colorimetry using TSGF reagent knit in 65 patients with intracranial tumors and 30 healthy people as normal controls. 65 intracranial tumors including 38 cases malignant tumor patients and 27 cases benign tumor patients by pathological test after operation.RESULTS: The average value of TSGF in serum and urine of human intracranial tumors were (67.29±20.09) U/ml, (20.20±8.20) U/ml ,which were higher than those normal controls (38.9±11.98) U/ml, (11.41±3.29) U/ ml (P<0.05) ,respectively. The serum and urine TSGF in malignancies were (79.12±12.44) U/ml; (22.51±6.89) U/ml, which significantly were higher than those of benign,(50.46±16.7) U/ml4; (16.96±8.91) U/ml(P<0.01), respectively. The serum and urine TSGF in 38. postoperations with intracranial malignancies were (54.27±16.43) U/ml, (14.41±3.65) U/ml, which were less than those of preoperations, (79.12±12.44) U/ml; (22.51±6.89) U/ml (P<0.01), respectively. The levels of malignant intracranial tumors are not associated with their diameters (P>0.05). We found that the level of TSGF is in relation to early recurrence of postoperative patients with malignant intracranial tumors.CONCLUSION: TSGF can be a good malignant intracranial tumor maker, it can be used for early diagnosis, differentiating benign from malignancy, evaluating malignancy, predicting prognosis and early recurrence of postoperative patients with malignant intracranial tumors.